S. Rich

发表

The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.

B. Brundage, S. Rich, P. Levy, 1985, Circulation.

Pulmonary hypertension from chronic pulmonary thromboembolism.

B. Brundage, S. Rich, S. Levitsky, 1988, Annals of internal medicine.

Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment.

B. Brundage, S. Rich, Stuart Rich, 1989, Journal of the American College of Cardiology.

The potential role for ultrafast cardiac computed tomography in patients with stroke.

B. Brundage, S. Rich, E. Chomka, 1989, Stroke.

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

D. Badesch, D. Langleben, R. Bourge, 2000, Annals of internal medicine.

Thromboxane synthetase inhibition in primary pulmonary hypertension.

B. Brundage, S. Rich, K. Hart, 1987, Chest.

Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension.

S. Rich, C. Wolfkiel, E. Chomka, 1995, The American journal of cardiology.

Multimedia computer-assisted instruction in cardiology.

A W Sajid, J W Mayer, G A Ewy, 1995, Archives of internal medicine.

Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes.

B. Brundage, S. Rich, G. Pietra, 1986, Annals of internal medicine.

Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.

S. Rich, R. Vestal, S. Inbar, 1992, Journal of the American College of Cardiology.

Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.

S. Rich, R. Vestal, E. Kaufmann, 1995, Chest.